Orchard Therapeutics Licenses Potentially Life-Changing MPS-I Gene Therapy ProgramADA Severe Combined Immune Deficiency (ADA-SCID), Business, Gene Therapy, Gene Transfer Technologies, Hematopoietic Stem Cell Transplantation (HSCT), Hurler syndrome (MPS I), Licensing, Neurometabolic Disorders, Stem Cell TherapyOrchard Therapeutics secured an exclusive license for an ex vivo autologous hematopoietic stem cell gene therapy program for the treatment of MPS-I developed by SR-Tiget. Read more May 29, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-05-29 07:27:402019-05-29 13:15:04Orchard Therapeutics Licenses Potentially Life-Changing MPS-I Gene Therapy Program